Trials / Completed
CompletedNCT03181308
Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Tracon Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, nonrandomized, dose-escalation, Phase 1b study of carotuximab in combination with standard dose nivolumab in patients with NSCLC that has progressed on or after platinum-based chemotherapy or PD-1/PD-L1 checkpoint inhibition, as a single agent or with chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carotuximab (TRC105) | Anti Endoglin Antibody |
| DRUG | OPDIVO | Programmed Death Receptor-1 |
Timeline
- Start date
- 2017-11-09
- Primary completion
- 2019-07-22
- Completion
- 2019-07-22
- First posted
- 2017-06-08
- Last updated
- 2020-06-24
- Results posted
- 2020-06-24
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03181308. Inclusion in this directory is not an endorsement.